Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
about
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritiSafety of non-steroidal anti-inflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritisInternet hand x-rays: A comparison of joint space narrowing and erosion scores (Sharp/Genant) of plain versus digitized x-rays in rheumatoid arthritis patientsAutophagy and cancerAutophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphomaAssociation of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.Simple and sensitive HPLC method for the fluorometric determination of methotrexate and its major metabolites in human plasma by post-column photochemical reaction.A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.Practical determination of methotrexate in serum of rheumatic patients by LC-MS/MS."Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.Current and future management approaches for rheumatoid arthritis.Principles and current strategies for targeting autophagy for cancer treatment.IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialWill pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?Disease modification in migraine: a concept that has come of age?Infliximab treatment of rheumatoid arthritis and Crohn's disease.Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.Current and new antitumor necrosis factor agents in perspectiveAbatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysisA meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Basic immunosuppressive drugs outside solid organ transplantation.Abatacept: a novel treatment for rheumatoid arthritis.A method to measure cardiac autophagic flux in vivoImpact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.Leg lymphedema caused by iliopectineal bursitis associated with destruction of a rheumatoid hip joint: A case report.Limits of add-on trials: antirheumatic drugs.Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a studyLong-term use of adalimumab in the treatment of rheumatic diseases.The pros and cons of essential medicines for rich countries.The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Autophagy inhibitors.Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?Cost effectiveness of leflunomide in the treatment of rheumatoid arthritis in Japan.Treatment principles in the management of autoimmune myasthenia gravis.Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study.Exfoliative dermatitis induced by leflunomide therapy.Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
P2860
Q24235194-2D6E5269-8047-44FF-941E-16BD390F06E8Q24235995-ADB35CD3-787A-43D1-9CEE-98E0E0BC5862Q24791754-1D9B610B-8A3F-4BF3-ADA2-8E6512ABED58Q26865957-8745FF49-6703-4FFF-9D7E-FACC5101945CQ29622918-F2C30411-2A2B-4FB0-A7C6-5DE3B8880C2AQ30252113-8C68D9EC-ED29-4BED-B9F7-CFFEC7C73244Q33856060-8DBD6333-4312-43B9-BEB6-27291453AD66Q33983913-3AAA31FF-4502-40C8-A10C-995F4D5B17F4Q34158973-94DAD941-F2E9-4A24-8292-A46169EB860AQ34560568-E5C1E7F2-E524-4B6C-9400-8C9039694B90Q34731287-96F1FF71-BE9A-4B75-9CFD-F770EE2B1BE7Q34787732-12AC3F6B-1C63-466D-B442-058547B89D13Q34795777-52271655-3CD6-4E1E-951D-04C89E7EF496Q35024962-C0EFB6EC-8E87-4BAC-A1E8-7F2B5AE967BCQ35056865-C2A81247-18B2-46DB-A5F6-9B2F39DA0D1AQ35201036-7AE8F5AB-BAA2-4982-B781-E464CDC24FEBQ35637808-9D32A234-78E9-4832-9523-1AA007EDBC00Q35823636-EAE27C94-023E-4D62-833F-E024203FBCC9Q35907809-8C37F0A6-9225-4CEF-A232-7C65E9BBAC86Q36200678-4DCA0329-F970-4D6D-81D5-75CEB8F90325Q36407314-C92BBFB5-94F2-47A7-9197-D2E56119AC90Q36967284-C2841192-9647-4439-A88C-357C492CA4E3Q37007826-89F8999C-BE47-4898-9EC6-EFF86867D9F3Q37172804-1337181F-9812-41CF-9AB6-D4A6F323C389Q37231295-5A248137-9F79-43AC-83B1-A0C9F7D85ADCQ37258347-BE054717-3A78-4126-AF39-9D8C6D573C47Q37270882-04A30A63-939D-4393-A1AC-7F42700F1F58Q37358124-A079127D-1D29-4E67-BB84-4F1111F08C12Q37611815-1E9B7B2A-3209-4FAA-A1E0-A72C20DE7914Q37754083-1B775A34-F2F8-4DA2-AF00-2137149C7EDCQ37754481-D1C4533C-EEF0-40EC-B8A8-535278C39AB8Q37866288-CE9A3344-9AE9-4F9A-9143-F38D674E2B11Q38666985-B641A91B-FC29-452B-B7A3-E3CC685D4BCBQ39804633-F01E1080-3A3C-44D1-914D-EAE136C790EDQ43266399-164453F7-7A42-49ED-BC37-8AFCD8A4E8E6Q44128226-A7A00A07-7000-4EE0-A593-1E52F3801301Q44616888-B1181BC1-5CD4-469F-9A90-B1A62EB35065Q44699173-CF4B8682-6DC5-463B-BA52-303B6D4D3A0FQ44948330-A17D291A-D1AB-4C3C-8CB3-99C3AF80CCC6Q47209281-BEC33F03-54E6-4B36-BFFD-EDBB2798C41A
P2860
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@ast
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@en
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@nl
type
label
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@ast
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@en
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@nl
prefLabel
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@ast
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@en
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@nl
P1476
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
@en
P2093
P304
P356
10.7326/0003-4819-134-8-200104170-00013
P407
P577
2001-04-01T00:00:00Z